Skip to main content

Table 6 Health state utilities for HCV patients achieving SVR

From: Achieving sustained virologic response in hepatitis C: a systematic review of the clinical, economic and quality of life benefits

Method

Study

Value

Difference

SVR

Non-response/relapse

EQ5D

Thein et al. 2005 [93]

0.83

 

Chong et al. 2003 [95]

0.83

0.76c

0.07

 

Van Rooijen et al. 2011 [99]

0.84

0.70

0.14

SF-36

Thein et al. 2005 [93]

0.74–0.90

0.70–0.86b

0.04–0.05

SF-6D

Hsu et al. 2012 [103]

0.71

0.66c

0.05

 

John-Baptiste et al. 2009 [18]

0.71

0.65

0.06

HUI3

Thein et al. 2005 [93]

0.77

 

John-Baptiste et al. 2009 [18]

0.70

0.58

0.12

 

Hsu et al. 2012 [103]

0.70

0.57c

0.13

HUI

Chong et al. 2003 [95]

0.77

0.73c

0.04

TTO

John-Baptiste et al. 2009 [18]

0.89

0.84

0.05

 

Hsu et al. 2012 [103]

0.88

0.80c

0.08

SG

Thein et al. 2005 [93]

0.86

 

Chong et al. 2003 [95]

0.86

0.79c

0.08

VAS

Thein et al. 2005 [93]

0.74

 

Chong et al. 2003 [95]

0.74

0.70c

0.04

Not stated

Liu et al. 2012 [104]

0.933–1.00a

 

Chhatwal et al. 2013 [105]

1.00

  1. HUI3, Health Utilities Index Mark 3; SF-36, Medical Outcomes Study 36-item Short-Form Health Survey; SG, standard gamble; TTO, time trade off; VAS, visual analog scale.
  2. aAge-specific quality of life weight.
  3. bUntreated.
  4. cPatients with mild/moderate HCV or chronic infection.